Compliance Rate
Compliance Rate
31.0%
Compliant submissions
31
Incompliant submissions
69
Total trials
100
Your Clinical Trials
Showing 25 of 100 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/04/22
End: 01/06/22
Due: 01/07/22
Phase: N/A
Priority: Normal
Start: 01/14/22
End: 01/16/22
Due: 01/17/22
Phase: N/A
Priority: Normal
Start: 01/24/22
End: 01/26/22
Due: 01/27/22
Phase: N/A
Priority: Normal
Start: 02/03/22
End: 02/05/22
Due: 02/06/22
Phase: N/A
Priority: Normal
Start: 02/13/22
End: 02/15/22
Due: 02/16/22
Phase: N/A
Priority: Normal
Start: 02/23/22
End: 02/25/22
Due: 02/26/22
Phase: N/A
Priority: Normal
Start: 03/05/22
End: 03/07/22
Due: 03/08/22
Phase: N/A
Priority: Normal
Start: 03/15/22
End: 03/17/22
Due: 03/18/22
Phase: N/A
Priority: Normal
Start: 03/25/22
End: 03/27/22
Due: 03/28/22
Phase: N/A
Priority: Normal
Start: 04/04/22
End: 04/06/22
Due: 04/07/22
Phase: N/A
Priority: Normal
Start: 07/03/22
End: 07/05/22
Due: 07/06/22
Phase: N/A
Priority: Normal
Start: 10/01/22
End: 10/03/22
Due: 10/04/22
Phase: N/A
Priority: Normal
Start: 09/16/23
End: 09/18/23
Due: 09/19/23
Phase: N/A
Priority: Normal
Start: -
End: 01/31/05
Due: 01/31/06
Phase: N/A
Priority: Normal
Start: 01/31/96
End: 12/31/98
Due: 12/31/99
Phase: N/A
Priority: Normal
Start: 07/31/87
End: 07/31/88
Due: 07/31/89
Phase: N/A
Priority: Normal
Start: 09/30/77
End: 10/31/81
Due: 10/31/82
Phase: N/A
Priority: Normal
Start: 11/30/96
End: 02/28/99
Due: 02/28/00
Phase: N/A
Priority: Normal
Start: 06/30/94
End: 06/30/96
Due: 06/30/97
Phase: N/A
Priority: Normal
Start: 04/30/96
End: 12/31/01
Due: 12/31/02
Phase: N/A
Priority: Normal
Start: -
End: 11/30/95
Due: 11/30/96
Phase: N/A
Priority: Normal
Start: 07/31/98
End: 06/30/03
Due: 06/30/04
Phase: N/A
Priority: Normal
Start: -
End: 07/31/97
Due: 07/31/98
Phase: N/A
Priority: Normal
Start: 03/31/99
End: 09/30/06
Due: 09/30/07
Phase: N/A
Priority: Normal
Start: 06/30/87
End: 01/31/93
Due: 01/31/94
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study 3 | NCT00000002 | Organization 3 | user3@example.com | Incompliant | 2022-01-04 | 2022-01-06 | 2022-01-07 | 2025-07-01 | Sponsor | 2025-07-01 |
| Study 13 | NCT00000012 | Organization 13 | user3@example.com | Incompliant | 2022-01-14 | 2022-01-16 | 2022-01-17 | 2025-07-01 | Sponsor | 2025-07-01 |
| Study 23 | NCT00000022 | Organization 23 | user3@example.com | Incompliant | 2022-01-24 | 2022-01-26 | 2022-01-27 | 2025-07-01 | Sponsor | 2025-07-01 |
| Study 33 | NCT00000032 | Organization 33 | user3@example.com | Incompliant | 2022-02-03 | 2022-02-05 | 2022-02-06 | 2025-07-01 | Sponsor | 2025-07-01 |
| Study 43 | NCT00000042 | Organization 43 | user3@example.com | Compliant | 2022-02-13 | 2022-02-15 | 2022-02-16 | 2025-07-01 | Sponsor | 2025-07-01 |
| Study 53 | NCT00000052 | Organization 53 | user3@example.com | Compliant | 2022-02-23 | 2022-02-25 | 2022-02-26 | 2025-07-01 | Sponsor | 2025-07-01 |
| Study 63 | NCT00000062 | Organization 63 | user3@example.com | Incompliant | 2022-03-05 | 2022-03-07 | 2022-03-08 | 2025-07-01 | Sponsor | 2025-07-01 |
| Study 73 | NCT00000072 | Organization 73 | user3@example.com | Incompliant | 2022-03-15 | 2022-03-17 | 2022-03-18 | 2025-07-01 | Sponsor | 2025-07-01 |
| Study 83 | NCT00000082 | Organization 83 | user3@example.com | Incompliant | 2022-03-25 | 2022-03-27 | 2022-03-28 | 2025-07-01 | Sponsor | 2025-07-01 |
| Study 93 | NCT00000092 | Organization 93 | user3@example.com | Compliant | 2022-04-04 | 2022-04-06 | 2022-04-07 | 2025-07-01 | Sponsor | 2025-07-01 |
| Study 183 | NCT00000182 | Organization 83 | user3@example.com | Incompliant | 2022-07-03 | 2022-07-05 | 2022-07-06 | 2025-07-01 | Sponsor | 2025-07-01 |
| Study 273 | NCT00000272 | Organization 73 | user3@example.com | Incompliant | 2022-10-01 | 2022-10-03 | 2022-10-04 | 2025-07-01 | Sponsor | 2025-07-01 |
| Study 623 | NCT00000622 | Organization 23 | user3@example.com | Incompliant | 2023-09-16 | 2023-09-18 | 2023-09-19 | 2025-07-01 | Sponsor | 2025-07-01 |
| Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection | NCT00000872 | National Institute of Allergy and Infectious Diseases (NIAID) | user3@example.com | Incompliant | - | 2005-01-31 | 2006-01-31 | 2025-07-01 | - | 2025-07-14 |
| Soy Estrogen Alternative Study (SEA) | NCT00000612 | National Heart, Lung, and Blood Institute (NHLBI) | user3@example.com | Incompliant | 1996-01-31 | 1998-12-31 | 1999-12-31 | 2025-07-01 | - | 2025-07-14 |
| IV Cocaine Abuse: A Laboratory Model - 1 | NCT00000212 | New York State Psychiatric Institute | user3@example.com | Incompliant | 1987-07-31 | 1988-07-31 | 1989-07-31 | 2025-07-01 | - | 2025-07-14 |
| Beta-Blocker Heart Attack Trial (BHAT) | NCT00000492 | National Heart, Lung, and Blood Institute (NHLBI) | user3@example.com | Incompliant | 1977-09-30 | 1981-10-31 | 1982-10-31 | 2025-07-01 | - | 2025-07-14 |
| Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14 | NCT00000262 | University of Chicago | user3@example.com | Incompliant | 1996-11-30 | 1999-02-28 | 2000-02-28 | 2025-07-01 | - | 2025-07-14 |
| Lack of Acute Tolerance Development to Effects of Nitrous Oxide - 4 | NCT00000252 | University of Chicago | user3@example.com | Compliant | 1994-06-30 | 1996-06-30 | 1997-06-30 | 2025-07-01 | - | 2025-07-14 |
| Acute Withdrawal From Smoked Cocaine - 9 | NCT00000292 | National Institute on Drug Abuse (NIDA) | user3@example.com | Incompliant | 1996-04-30 | 2001-12-31 | 2002-12-31 | 2025-07-01 | - | 2025-07-14 |
| A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection | NCT00000652 | National Cancer Institute (NCI) | user3@example.com | Incompliant | - | 1995-11-30 | 1996-11-30 | 2025-07-01 | - | 2025-07-14 |
| Preventing Child Abuse in Infants | NCT00000382 | University of Rochester | user3@example.com | Compliant | 1998-07-31 | 2003-06-30 | 2004-06-30 | 2025-07-01 | - | 2025-07-14 |
| A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides | NCT00000802 | National Institute of Allergy and Infectious Diseases (NIAID) | user3@example.com | Incompliant | - | 1997-07-31 | 1998-07-31 | 2025-07-01 | - | 2025-07-14 |
| A Study of the Long-Term Outcomes of HIV-Positive Patients | NCT00000932 | National Institute of Allergy and Infectious Diseases (NIAID) | user3@example.com | Incompliant | 1999-03-31 | 2006-09-30 | 2007-09-30 | 2025-07-01 | - | 2025-07-14 |
| Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome | NCT00000572 | Intermountain Health Care, Inc. | user3@example.com | Incompliant | 1987-06-30 | 1993-01-31 | 1994-01-31 | 2025-07-01 | - | 2025-07-14 |